Keenova Presents New TERLIVAZ® (terlipressin) Data Analyses at Kidney Week 2026

Keenova Therapeutics said two analyses of TERLIVAZ (terlipressin) for hepatorenal syndrome-acute kidney injury will be presented at ASN Kidney Week 2026, including a retrospective real-world study and an exploratory subgroup analysis of the CONFIRM trial; the release reports no study results. The company cited U.S. inpatient diagnoses of HRS rising from an estimated 42,930 in 2018 to 63,381 in 2023. TERLIVAZ carries a boxed warning for serious or fatal respiratory failure, with higher risk in patients with volume overload or ACLF Grade 3.

Analysis

The release is an event calendar, not new efficacy evidence: without the posters’ effect sizes, comparator details, safety rates, or utilization data, the presentations do not yet support a meaningful revision to TERLIVAZ revenue assumptions. The key commercial question is not the expanding HRS burden but how many hospitalized patients are clinically eligible and treated after accounting for hypoxia, volume overload, ACLF severity, and transplant priorities. Those constraints can materially limit conversion from diagnosed cases to drug demand.

The October 22 real-world analysis could be more commercially informative if it demonstrates routine adoption and outcomes beyond trial settings; the October 24 transplant-ineligible subgroup may address a particularly important treatment decision, but exploratory findings should not be treated as definitive. In the near term, expect a low-signal catalyst unless data show a clear change in practice. Over 1–3 months, monitor whether clinicians’ interpretation changes prescribing and hospital protocols. Over 6–18 months, persistent respiratory-safety concerns or adverse events that compromise transplant eligibility could constrain adoption even if kidney-function outcomes are favorable.

The contrarian point is that rising HRS diagnoses do not translate directly into a larger addressable market: acuity, contraindications, competing care pathways, and hospital execution may dominate. Conversely, credible real-world evidence of safe use in appropriately selected patients could support adoption without changing the label. No ticker mapping or financial data were supplied, so a company-specific valuation or pair trade is not supportable.

Key Decisions for Investors

• Do not trade the announcement alone; review the October 22 and 24 presentations for absolute outcome rates, comparator construction, treatment selection, respiratory events, and renal-replacement-therapy results before changing estimates.
• Set an alert for evidence that real-world treatment is expanding among eligible patients, rather than relying on national diagnosis counts. Verify utilization, treated-patient mix, and discontinuation data in subsequent company disclosures.
• Treat safety and transplant eligibility as the principal downside monitors. A rise in respiratory failure, ischemic events, or evidence that treatment delays or jeopardizes transplantation would falsify an adoption thesis; favorable subgroup results without adequate safety detail would not resolve that risk.
• No actionable long/short recommendation on the supplied information. Reassess only if the conference data produce a demonstrable practice-changing signal or subsequent reporting confirms a material shift in utilization.